SecBot SecBot
Biotech Drug Report Generated Nov 9, 2026

intismeran

MRNA·Moderna, Inc.
NEUTRAL
Drug Impact Rating6/10
Trial phase
Phase 3 (completed)
Time to market
BLA submission planned by end of 2026; regulatory approval targeted for 2027 if the FDA accepts and reviews the application on a standard timeline.
Why 6/10
The next hard catalyst is the planned BLA submission for intismeran in melanoma by end of 2026 (about 1-2 months away), as stated on Moderna's Q3 2026 earnings call. This is a milestone event but not a binary regulatory decision; the actual PDUFA approval decision would follow in 2027. The drug is a major pipeline value driver for Moderna, but Moderna also has approved COVID and RSV products, so the company is not a single-asset binary.
Actionable Insight NEUTRAL

Watch for Moderna's BLA submission for intismeran in melanoma by end of 2026. A submission would confirm the regulatory path is on track, while any delay would be a negative signal. The actual PDUFA decision (likely in 2027) is the true binary catalyst. The stock has already rallied ~978% over the past year, and the mean analyst price target of $145 implies ~42% downside from the current ~$259, suggesting much of the good news may already be priced in.

Price Chart

Loading chart...

Executive Summary

Intismeran (also known as intismeran autogene, V940, or mRNA-4157) is a personalized mRNA cancer therapy co-developed by Moderna (MRNA) and Merck (MRK). In October 2026, the Phase 3 INTerpath-001 trial met its primary endpoint: intismeran plus Keytruda reduced the risk of melanoma recurrence or death by 42% versus Keytruda alone in patients with resected high-risk melanoma. Detailed results were presented at the ESMO 2026 Presidential Symposium. Moderna management stated on the Q3 2026 earnings call that it plans to submit a Biologics License Application (BLA) by end of 2026, targeting regulatory approval in 2027. The stock has already rallied ~978% over the past year, and the mean analyst price target of ~$145 implies significant downside from the current ~$259 price, suggesting much of the optimism may already be priced in.

How It Works

Intismeran is a personalized mRNA cancer therapy. Doctors first sequence a patient's tumor to find its unique genetic mutations (neoantigens). Then a custom mRNA vaccine is manufactured that teaches the patient's immune system to recognize and attack cells carrying those specific mutations. It is designed to be used in combination with Merck's immunotherapy Keytruda (pembrolizumab), which takes the brakes off the immune system, so the two drugs work together: the vaccine tells immune cells what to target, and Keytruda keeps those cells active.

Trial Status

The pivotal Phase 3 INTerpath-001 trial in resected stage IIB-IV melanoma met its primary endpoint (recurrence-free survival) and key secondary endpoint (distant metastasis-free survival). Detailed results were presented at ESMO 2026 in October. A separate Phase 3 trial in cutaneous squamous cell carcinoma (V940-007, NCT06295809) was terminated. The companies have also demonstrated successful large-scale manufacturing, serving 99% of trial patients with personalized vaccines.

The Two-Sided Case

▲ Bull Case7
Phase 3 INTerpath-001 trial met its primary endpoint: intismeran + Keytruda reduced risk of melanoma recurrence or death by 42% (HR=0.58, p<0.001) vs Keytruda alone in 1,137 patients with resected stage IIB-IV melanoma (per ESMO 2026 presentation and Reuters).
The drug also met the key secondary endpoint of distant metastasis-free survival, reducing risk of spread by 38%.
Intismeran is a potential first-in-class individualized neoantigen therapy (INT), a personalized mRNA cancer vaccine encoding up to 34 patient-specific neoantigens.
Management plans to submit a BLA by end of 2026 with a goal of regulatory approval in 2027 (per Moderna Q3 2026 earnings call).
The drug has FDA Breakthrough Therapy designation for adjuvant treatment of high-risk melanoma (granted February 2023).
Merck and Moderna demonstrated successful large-scale manufacturing, serving 99% of trial patients with personalized vaccines (per BioSpace, Nov 2026).
Moderna reported a profitable Q3 2026 ($162M net income) and raised full-year revenue growth guidance to 15-25%.
▼ Bear Case6
Analyst consensus is 'hold' with a mean price target of $145.42, implying ~42.8% downside from the current ~$259 stock price.
The stock has already rallied ~978% over 12 months (per quant signals), suggesting much of the intismeran upside may already be priced in.
A Phase 3 trial of intismeran in cutaneous squamous cell carcinoma (NCT06295809) was terminated, limiting the initial addressable market to melanoma alone.
Manufacturing personalized mRNA vaccines for each patient is complex and expensive; Merck's CEO has had to address cost concerns publicly.
The stock is highly volatile (HV30 of 101%, HV90 of 196% per quant signals), and the stock fell ~17% on the day Phase 3 data were released (the data leak caused a 'sell the news' reaction).
Moderna faces ongoing revenue uncertainty as COVID vaccine sales decline from pandemic peaks.

Upcoming Catalysts

  • BLA submission to FDA by end of 2026 (targeted per Moderna Q3 2026 earnings call)
  • Potential FDA acceptance and PDUFA date assignment in 2027
  • Potential regulatory decisions in other markets (EU, etc.)
  • Possible expansion into other cancer indications beyond melanoma

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Moderna, Inc. 8-K MRNA ·Originating report

Sources · 5

Hover a chip for the title
1 reuters.com2 biospace.com3 ajmc.com4 managedhealthcareexecutive.com5 arstechnica.com